Publications & Posters

All categories

Publications

Posters

All Cell Engagers

AFM11

AFM13

AFM24

AFM26

All years

2020

2019

2018

2017

2016

2015

2014

2013

2012

2011

2010

2009

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Bartlett et al.
ASH 2018 - AFM13-103

CD16A-Specific Tetravalent Bispecific Immuno-Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) by Macrophages

Wingert et al.
ASH 2018 - Macrophages

Redirected Optimized Cell Killing: ROCK - A next generation immune cell engager platform

Ross et al.
ASH 2018 - AFM26

Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202).

Sawas et al.
ASH 2018 - AFM13-102

A Phase 1 Study Investigating AFM11 in Patients with Relapsed/Refractory B-cell Precursor Acute Lymphoblastic Leukemia: Preliminary Results

Salogub et al.
ASH 2018 - AFM11

A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data

Bartlett et al.
23rd Congress of EHA – AFM13

CD16A Activation of NK Cells Promotes NK Cell Proliferation and Memory-Like Cytotoxicity against Cancer Cells

Pahl et al.
Cancer Immunol Res 2018; 6:517-527.

link to publication

Pharmacokinetics and in vitro/in vivo characterization of high-affinity bispecific EGFR/CD16A NK cell engagers for the treatment of EGFR-expressing tumors

Kluge et al.
AACR 2018 – AFM24

Recombinant Antibodies to Arm Cytotoxic Lymphocytes in Cancer Immunotherapy.

J. Koch, M. Tesar
Transfus Med Hemother 2017; 44:337-350.

link to publication

Trispecific antibodies for CD16A-directed NK cell engagement and dual-targeting of tumor cells.

Gantke et al.
Protein Eng Des Sel. 2017 Aug 17:1-12. doi: 10.1093/protein/gzx043.

link to publication

1
2
3
4
5